University Health Network

Arch Biopartners Inc. announces the start of patient recruitment and dosing in Canada for the Phase II trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI). The University of Calgary has already dosed the first patient, and Toronto hospitals are finalizing approvals. The trial aims to evaluate the percentage of subjects with AKI within seven days post-surgery, using KDIGO criteria.

Srikala Sridhar discusses the application of Bicycle® toxin conjugate zelenectide pevedotin (BT8009), targeting nectin-4 in urothelial cancer, similar to enfortumab vedotin but with potential reduced toxicity. The phase 2/3 Duravelo-2 trial (NCT06225596) evaluates zelenectide pevedotin in treatment-naive and previously treated patients, aiming to confirm efficacy and safety.

Simple hysterectomy reduced sexual dysfunction risk vs radical hysterectomy in low-risk, early-stage cervical cancer patients, with noninferior oncologic outcomes. Better sexual health and quality-of-life outcomes were observed in the simple hysterectomy group.

650 bilateral EVLP cases (2008-2022) at Toronto General Hospital, with 1300 radiographs, were split 80:20 into training and validation sets. CNN architectures (ResNet-50, ResNeXt-50, RexNet-100, EfficientNet-B2/B3, DenseNet-121) were pretrained on ChestX-ray14 datasets and finetuned on EVLP radiographs for lung transplant outcome classification. Model performance was evaluated using accuracy and AUROC. GradCAM was used for CNN interpretation, and XGBoost models analyzed EVLP data and latent CNN features.

Viatris launches Viagra ODF, an orodispersible film for ED treatment in Canada, offering convenience and discretion, with a 50 mg dose at similar pricing to Viagra tablets.

The TRIPOD+AI update provides harmonised guidance for reporting prediction model studies, superseding TRIPOD 2015, to accommodate AI and machine learning methods. The new 27-item checklist aims for complete, accurate, and transparent reporting, facilitating study appraisal and model implementation.

Arch Biopartners announces Alberta Health Services approval for Phase II trial of LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial, targeting 240 patients, is set to begin recruitment in September at multiple international sites.